Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Ovarian Neoplasms 2Melanoma 2Endometrial Neoplasms 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Thyroid Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Rectal Neoplasms 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Multiple Myeloma 1Moderate Hepatic Impairment 1Meningioma 1Lymphoma 1Lung Neoplasms 1Locally Advanced (Inoperable) or Metastatic Breast Cancer 1Hematologic Neoplasms 1Glioma 1Esophageal Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1Chondrosarcoma 1Carcinosarcoma 1Carcinoma, Renal Cell 1Carcinoma, Hepatocellular 1Carcinoma, Endometrioid 1Breast Neoplasms 1

Interventions

capivasertib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Moderate Hepatic Impairment × capivasertib × 30 days × Clear all
NCT07343960 2026-05-20

A Phase I Study to Investigate the Pharmacokinetics and Safety of Capivasertib in Participants With Moderate Hepatic Impairment

AstraZeneca

Phase 1 Recruiting
20 enrolled

Moderate Hepatic Impairment

Data powered by HemOnc (CC BY 4.0) Colophon âš¡